Skip to main content
. Author manuscript; available in PMC: 2018 Nov 9.
Published in final edited form as: J Med Chem. 2017 Oct 25;60(21):8906–8922. doi: 10.1021/acs.jmedchem.7b01154

Figure 8.

Figure 8

Prolongation of skin allograft by compound 10. C57BL6 mice were transplanted with Balb/c skin grafts and treated with 250 µg of CTLA4-Ig (days 0, 2, 4, and 6) plus either CD40L antibody (MR-1; 250 µg; days 0, 2, 4, and 6) or compound 10 (30 mg/kg; daily, s.c. in 20% HPβCD) following the protocol from87. Data are with a total of 5–8 mice per group. *p < 0.05, ***p < 0.001 compared to CTLA4-Ig alone using log-rank (Mantel-Cox) test.